Personal profile
Biography
Prof. Egan graduated from UCG in 1990 (M.B., B.Ch., B.A.O.), and completed internship, house officer and registrar training, based at University College Hospital Galway. He received Membership of RCPI in 1992, and Masters in Medical Science from UCG in 1994. From 1994 to 1999, at the Mayo Clinic in Minnesota he completed further training in Internal Medicine, Clinical Pharmacology amp; Gastroenterology, receiving American Board certification in those 3 disciplines. NUI Galway conferred an MD in 1999. Prof. Egan then undertook post-doctoral training from 2000 to 2002, in the Laboratory of Mucosal Immunology at the University of California, San Diego, before returning to the Mayo Clinic to take up a consultancy in Gastroenterology, with joint appointment in the Department of Molecular Pharmacology and Experimental Therapeutics. His research focuses on molecular characterization of signaling pathways involved in intestinal epithelial cell stress, death and malignant transformation, and optimization of personalized approaches to biological therapy in inflammatory bowel diseases. In 2005, Prof. Egan joined NUI Galway and the Health Service Executive Western Region as Professor of Clinical PharmacologyConsultant Clinical Pharmacologist and Head of the Department of Pharmacology amp; Therapeutics, a position he took up in August 2005. Prof. Egan has served as Interim Director of the HRB Clinical Research facility Galway, as Vice-Dean of Research at the College of Medicine Nursing and Health Sciences at NUI Galway, and as Head of the discipline of Pharmacology and Therapeutics. He is a past-President of the Irish Society of Gastroenterology. He was associate editor at Gut, and has been editor-in-chief of the Journal of Crohns and Colitis since 2014.
Education/Academic qualification
MB BCH BAO MRCPI MD
Accepting PhD Students
- Accepting PhD Students
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
A single-centre analysis of a biosimilar switching programme for adalimumab in inflammatory bowel disease
Rabbitt, L., Keogh, Á., Duane, L., Ferguson, J., Hobbins, A., McGuire, B. E., Gillespie, P. & Egan, L. J., Sep 2025, In: British Journal of Clinical Pharmacology. 91, 9, p. 2628-2635 8 p.Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review
Open Access -
Barriers, Drivers, and Outcomes in Transitioning Patients with Inflammatory Bowel Disease from Intravenous to Subcutaneous Infliximab
Campion, J. R., McCormick, E., Finn, K., Keogh, A., Duane, L., Jose, R., Egan, L. J., Slattery, E. & Hussey, M., 1 Jul 2025, In: Crohn's and Colitis 360. 7, 3, otaf008.Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review
Open Access -
Effectiveness, safety, and cost of combination advanced therapies in inflammatory bowel disease
McShane, C., Varley, R., Fennessy, A., Byron, C., Campion, J. R., Hazel, K., Costigan, C., Ring, E., Marrinan, A., Judge, C., Sugrue, K., Cullen, G., Dunne, C., Hartery, K., Iacucci, M., Kelly, O., Leyden, J., McKiernan, S., O'Toole, A. & Sheridan, J. & 8 others, , Jan 2025, In: Digestive and Liver Disease. 57, 1, p. 274-281 8 p.Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review
6 Citations (Scopus) -
Endocannabinoid system modulation for visceral abdominal pain in inflammatory bowel disease and irritable bowel syndrome: A protocol for systematic review and meta-analysis
Lane, R. M., Egan, L. J., McGuire, B. E., McKernan, D. P., O'Mahony, S. M. & Finn, D. P., 2025, In: HRB Open Research. 8, 40.Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review
Open Access -
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
QUASAR Study Group, 4 Jan 2025, In: The Lancet. 405, 10472, p. 33-49 17 p.Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review
72 Citations (Scopus)
Activities
- 1 Current Postgraduates (Research) Supervised
-
Rebecca Lane
Egan, L. J. (Co-Supervisor)
2024Activity: Other › Current Postgraduates (Research) Supervised